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Abstract
Myocardial perfusion studies are among the most often per­
formed investigations in Nuclear Medicine. However, the deve­
lopment of radiopharmaceuticals for cardiology is an emerging 
discipline and several other radiotracers have been proven to be 
useful. Although the myocardial perfusion studies have a well­
established role in the management of cardiac disorders, still 
a number of radiopharmaceuticals are under development for 
a variety of specific cardiac indications and their eventual clinical 
role remains to be seen. The paper provides a short overview 
of currently used radiopharmaceuticals and potential molecular 
imaging radiotracers applicable in cardiology. 
Key words: nuclear medicine, nuclear cardiology, cardiac 
imaging radiopharmaceuticals, status and trends
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Introduction
Myocardial perfusion studies are among the most often 
performed investigations in Nuclear Medicine. That high number 
of studies is facilitated by the availability of suitable tracers radi-
olabelled with 99mTc. Hence, the technetium agents were used 
for more than 90% of the 8 million cardiac imaging studies in the 
US in 2006 [1] out of a total of over 20 million nuclear medicine 
procedures. The number of cardiac imaging studies performed 
in Europe is generally lower than in US and it is varying between 
European countries. In Poland utilization of the nuclear cardiol-
ogy procedures performed in 2008 accounted for little over 11 
per cent of the total number of nuclear medicine procedures [2]. 
However, the development of radiopharmaceuticals for cardiology 
is an emerging discipline and several other radiotracers have been 
proved to be useful. The aim of this paper is to provide the brief 
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overview of the radiopharmaceuticals available today and also on 
the tracers which are entering the field. 
Myocardial perfusion 
Myocardial perfusion imaging is a well established noninvasive 
method of assessing coronary blood flow. It is capable of iden-
tifying regional abnormalities in coronary artery blood flow and 
determining their physiological relevance to myocardial function 
and viability. Used frequently in conjunction with either physical 
exercise or pharmacological stress, the myocardial perfusion 
imaging is useful in unmasking myocardial perfusion deficits not 
evident at rest [3].
Among the earliest developed radiopharmaceuticals used in 
cardiology there were tracers for measurement of myocardial blood 
flow [4]. The first radioactive tracer used to asses perfusion was po-
tassium-43, because of its avid extraction and retention. Since the 
1970’s, thallium-201 (201Tl, t1/2=73 h) has been used extensively 
as myocardial perfusion agent for assessing myocardial viability 
[5]. The uptake of these tracers occurs predominantly through 
the Na+/K+ channel. For 201Tl, the rapid myocardial extraction 
depends on perfusion, whereas the myocardial retention/redistri-
bution reflects myocardial viability. In the 1980’s, lipophilic tech-
netium-99m complexes were demonstrated as good myocardial 
perfusion agents [6]. Currently, sestamibi [7] and tetrofosmin [8] 
are approved agents by FDA, sestamibi is also approved in EU. 
Recently a number of generic sestamibi kits have been granted 
marketing authorization. The most frequently used SPECT and PET 
tracers for assessing myocardial blood flow are presented in Table 
1. Their more detailed characteristics is given below. 
SPECT perfusion tracers
Thallous (201Tl) chloride injection 
USP [10], Ph. Eur. [11] (monograph 0571). 201Tl is a cyclotron 
produced radionuclide with the half-life of 73 hours. For many 
years, planar imaging and SPECT with thallium-201 chloride 
constituted the only scintigraphic technique available for detecting 
coronary artery disease and assessing prognosis in patients un-
dergoing stress perfusion imaging [12]. The chemical properties of 
this monovalent cation result that it acts similarly to potassium and 
is taken into viable cardiac myocytes. It distributes in cardiac tissue 
roughly in proportion to regional blood flow. In practice, it is injected 
when the patient is at peak exercise or shortly after the pharma-
cologic stress agent is administered. Defects on the initial image 
can represent regional ischemia or nonviable myocardium. As the 
cardiac stress is discontinued, the thallium-201 redistributes and 
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fills in areas that were underperfused due to ischemia (reversible 
defect). Regions of the heart that have been irreversibly damaged 
by previous myocardial infarction do not demonstrate resolution of 
the defect on the delayed image (fixed defect). In this way, the test 
can discriminate the regions of inducible ischemia at risk for future 
myocardial infarction and areas that have been already irreversibly 
damaged by prior myocardial infarction. Thallium-201 has several 
virtues as a myocardial perfusion agent [13]. It is characterized by 
regional blood clearance half-time of < 30 s and a first pass ex-
traction in the myocardium of > 88%, while 99mTc-sestamibi blood 
clearance half-time is > 1 min and a first pass extraction in the 
myocardium is 50% to 60%. These biological characteristics of 
thallium provide higher contrast between regions of normal perfu-
sion and zones of ischemia, even on planar myocardial perfusion 
studies (see Table 1). Some physical and biological characteris-
tics of thallium, however, are not so favorable. The electron capture 
decay of 201Tl produces 88 X-ray photons at 70 to 80 keV and 
approximately 12 gamma photons at 135 and 167 keV for each 
disintegration. In addition to the low energy of the predominant 
photon, the physical half-life of 73 h and biological half-life of ap-
proximately 10 days (240 h) results in a relatively long effective 
half-life of approximately 56 h. In addition to myocardium, skeletal 
muscle and liver, the tracer also localizes in the testes and kidneys, 
producing an affective dose equivalent to 34.5 mSv/150 MBq. Due 
to relatively high absorbed dose the administered radioactivity of 
201Tl is usually limited to well below 150 MBq, which in turn may 
limit the image quality. 
Technetium (99mTc) sestamibi injection 
USP [10], Ph. Eur. [11] (monograph 1926). 99mTc-sestamibi 
(99mTc-MIBI; Fig. 1) is a cationic, lipophilic complex that consists of 
1 atom of 99mTc in a 1+ oxidation state and 6 molecules of 2-meth-
oxyisobutylisonitrile (MIBI). 
Sestamibi contains isonitrile groups that form a complex with 
99mTc after reduction with stannous ions. Since isonitriles are vola-
tile and unstable compounds, MIBI is available in stabilized form 
as copper tetrafluoroborate adduct, [Cu(MIBI)4]BF4, which should 
be decomposed during radiolabelling carried out at elevated 
temperature. Lyophilized Sestamibi kits (Cardiolite, 99mTc-MIBI 
kit, CardioTop, Technescan Sestamibi, etc.) contain a mixture of 
[tetrakis(2-methoxy-2-methylpropyl-1-isocyanide)copper (1+)] 
tetrafluoroborate as the active substance, and excipients like: 
stannous chloride (reductant), L-cysteine hydrochloride (ancillary 
reductant), sodium citrate (buffering substance), and mannitol 
(bulking agent). Radiolabelling is carried out by adding a suf-
ficient amount of sterile, non-pyrogenic, oxidant-free sodium 
pertechnetate (99mTc) eluate from the 99Mo/99mTc generator to the 
kit vial and heating the mixture in a boiling water bath for 10 min. 
The potential radiochemical impurities present in 99mTc-sestamibi 
preparation that can affect image quality are: pertechnetate 
(99mTc) ion, technetium-99m in colloidal form, and 99mTc-pentamibi 
dimethylvinyl isonitrile ((OC-6-22)-pentakis[1-(isocyano-kC)-2-me-
thoxy-2-methylpropane][1-(isocyano-kC)-2-methylprop-1-ene]
[99mTc]technetium(1+)). 
The U.S. Pharmacopeia requires that a mean of not less than 
90% of the total radioactivity is represented by 99mTc-sestamibi, and 
a mean of not more than 5% of the total radioactivity is present 
as 99mTc-pentamibi dimethylvinyl isonitrile. The quality require-
ments for sestamibi are also set in the European Pharmacopoeia 
monograph 1926 and they are stringent, i.e.: technetium-99m 
sestamibi: minimum 94 per cent of the total radioactivity; sum 
of pertechnetate (99mTc) ion and other polar impurities and 
technetium-99m in colloidal form: maximum 5 per cent of the total 
radioactivity; 99mTc-pentamibi dimethylvinyl isonitrile: not more than 
3 per cent of the total radioactivity.
Table 1. Comparison of the main blood flow tracers. Table derived from [9] 
Tracer Physical half-life Myocardial  
extraction (%)*
Clearance  
half-life
Viability
SPECT
Thallium-201 73 h 85 Slow +++
99mTc-sestamibi 6 h 65 Very slow ++
99mTc-tetrofosmin 6 h 60 Very slow ++
PET
Rubidium-82 76 s 65 Slow ++
13N-ammonia 10 min 80 Very slow +
15O-water 2 min 100 Fast ++
*Extraction is flow dependent; values given represent estimates at resting flow rates. 
Figure 1. Structure of 99mTc­sestamibi ((OC­6­11)­hexakis[1­
(isocyano­kC)­2­methoxy­2­methylpropane] [99mTc]technetium(I) chlo­
ride)
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99mTc-sestamibi is used as a substitute for 201Tl for myocardial 
perfusion imaging. It is used primarily for detection of myocardial 
perfusion abnormalities, particularly for detection of myocardial 
ischemia and infarcts. This radiopharmaceutical is also useful 
for the assessment of myocardial function using the first-pass ra-
dionuclide ventriculographic technique (FPRV). 99mTc-sestamibi 
is taken up by the cells of the myocardium in passive diffusion and 
then appears in the cytosol and is localized in the mitochondria. 
The uptake is proportional to the myocardial perfusion, and the 
washout is rather slow (excluding considerable redistribution). 
At stress, more than 3% of the injected dose is accumulated in 
the myocardium, while the nonbound part is eliminated via the 
hepatobiliary route. Technetium-99m sestamibi acts as a calcium 
analog when taken up by the heart. Once taken by myocardial 
myocytes, redistribution does not occur as it does for the thal-
lium-201. Consequently, when performing a technetium-99m scan, 
a second injection is given at the time of the delayed image [14].
Technetium (99mTc) tetrofosmin injection 
USP [10]. 99mTc-tetrofosmin is a cationic complex of tech-
netium-99m at the oxidation state 5+ and two molecules of 
tetrofosmin ([6,9-bis(2-ethoxyethyl)-3, 12-dioxa-6,9-diphospha-tet-
radecane] (Fig. 2). The chemical formula of the 99mTc-complex 
is [99mTc(tetrofosmin)2O2]
+ with a charge of 1+.
99mTc-tetrofosmin is a diagnostic radiopharmaceutical used 
in nuclear medicine cardiac imaging [8]. It is commercially 
available as lyophilized kit under the brand name Myoview (GE 
Healthcare). The Myoview kit contains a lyophilised mixture of 
0.23 mg of tetrofosmin as the active substance and excipients: 
stannous chloride dehydrate, disodium sulfosalicylate, sodium 
D-gluconate, and sodium hydrogen carbonate. Radiolabelling 
is carried out by adding sodium pertechnetate (99mTc) eluate from 
the 99Mo/99mTc generator to the kit vial and incubating the mixture 
for 15 min at room temperature. 99mTc-gluconate is initially formed 
with reduced 99mTc, which is obtained by stannous ion reduction, 
and then ligand exchange between 99mTc-gluconate and the 
tetrofosmin group gives 99mTc-tetrofosmin. The radiochemical 
purity of 99mTc-tetrofosmin should not be less than 90% of the total 
radioactivity [15]. 
Uptake of 99mTc-tetrofosmin in the myocardium and in tu-
mours and metastases is similar to that of 99mTc-MIBI [16]. The myo-
cardial uptake of 99mTc-tetrofosmin appears to occur by a passive 
diffusion process (no redistribution). Intravenously administered, it 
is rapidly taken up by myocardial tissue and reaches its maximum 
level in approximately 5 minutes. 66% of the total injected dose 
is excreted within 48 hours after injection (40% urine, 26% feces). 
99mTc-tetrofosmin is indicated for use in scintigraphic imaging of 
the myocardium under stress and rest conditions. It is used to 
determine areas of reversible ischemia and infarcted tissue in the 
heart. It is also indicated to detect changes in perfusion induced by 
pharmacologic stress (adenosine) in patients with coronary artery 
disease. When injected at stress, 99mTc-tetrofosmin accumulates in 
viable myocardial tissue in relation to myocardial blood flow; thus, 
ischemic areas (e.g., those supplied by stenotic vessels) are 
detectable as areas of less accumulation. Its third indication is to 
assess left ventricular function (ejection fraction) in patients thought 
to have heart disease. 
PET perfusion tracers
Several positron-emitting radionuclides are also utilized to 
obtain tomographic images of regional myocardial perfusion (see 
Table 1), metabolism and the receptor density [17]. Four different 
approaches have been utilized for assessment of myocardial 
via bility: (1) perfusion-FDG metabolism imaging, (2) determina-
tion of oxidative metabolism with 11C-acetate, (3) uptake and 
retention of 82Rb and (4) the water perfusable tissue index [5]. 
These PET tracers not only allow for the diagnosis of coronary 
artery disease with a high degree of sensitivity and specificity, but 
using mathematical models also allow quantitative assessment 
of myocardial perfusion.
Rubidium (82Rb) chloride injection 
USP [10]. Rubidium-82 chloride has been introduced 
as tracer for myocardial imaging in consequence of searching 
for positron-emitting analogue of 201Tl with improved physical 
characteristics. 82Rb has a half-life of 76 s and maximum b+ 
energy of 3.3 MeV. It is obtained by decay of parent radionuclide 
82Sr from a generator system with hydrous stannic oxide column. 
Strontium-82 decays to 82Rb with a half-life of 25 days (600 hrs), 
hence the useful life of a generator is about 1 month. Because 
of the short half-life of the daughter radionuclide, the generator 
can be eluted at 10 min intervals with high yield. The generator 
is eluted with saline and eluate is infused directly to the patient 
as 82Rb chloride in saline. Today the 82Sr/82Rb generators are of-
fered by Bracco Diagnostic Inc (US) as CardioGen-82 (Rubidium 
Rb 82 Generator) [18]. The design and validation of an in-house 
generator has been also published [19]. 
Gould et al. [20] showed that 82Rb is a short-lived tracer useful 
for myocardial perfusion imaging. 82Rb is a cation, with an intra-
cellular uptake across the cellular membrane that reflects active 
transport. It behaves as an analogue of potassium and is taken up 
into the heart actively by Na+/K+ ATPase pump. It is rapidly cleared 
from the blood and taken up to a variable degree by all tissues and 
organs except brain. The short half-life of 82Rb permits the entire 
rest/stress protocol to be completed within 45 minutes, which 
is very convenient for the patient. 82Rb has favorable physiologic 
and physical properties, however it is a difficult tracer to image. It 
emits an unusually high-energy positron, which can travel a con-Figure 2. Structure of 99mTc­tetrofosmin.
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siderable distance in tissue before annihilating, thereby affecting 
global image quality [21]. 
Ammonia (13N) injection 
USP [10], Ph. Eur. [11] (monograph 1492). 13N has a half-life of 
10 minutes and maximum b+ energy 1.2 MeV (must be obtained 
from an on-site cyclotron). It is prepared by proton irradiation of 
water target in cyclotron followed by reduction, distillation and 
trapping in a slightly acidic solution. Ammonia equilibrates with 
ammonium ion in the blood stream. It is the neutral ammonia spe-
cies, which diffuses across biological membranes into cells and 
is enzymatically converted into glutamine. First pass extraction 
is 80% at normal flow but falls off at high flow rates. It is rapidly 
cleared from circulation and extracted by liver (15%), lungs, myo-
cardium (2-4%), brain, kidney and bladder. Initial uptake in the 
lungs clears rapidly allowing visualization of the heart. A complete 
rest/stress protocol requires about 2 hours to allow for decay of 13N 
between studies. Using 13N-ammonia the absolute quantification 
of myocardial perfusion can be performed [17].
Water (15O) injection 
USP [10], Ph. Eur. [11] (monograph 1582). 15O-water is widely 
used for measurement of regional cerebral perfusion, but can also 
be used in the heart. O-15 has a half-life of 2 minutes and maximum 
b+ energy 1.7 MeV (must be obtained from the on-site cyclotron, 
formed in the reaction of molecular oxygen with small amount of 
hydrogen). It diffuses freely across membranes and enters total 
body water space. Delivery of 15O-water to myocardial (and other) 
cells is efficient but rapid washout occurs, which necessitates dy-
namic imaging or subtraction of blood pool activity. The short 
half-life allows a conveniently short rest/stress imaging protocol 
but can result in poor counting statistics. Absolute quantification 
can be performed [17]. 
Myocardial oxygen consumption
Sodium acetate ([1-11C]) injection 
USP [10], Ph. Eur. [11] (monograph 1920). 11C-acetate 
is a tracer of citric acid cycle and thus directly of oxidative me-
tabolism, allowing assessing myocardial oxygen consumption and 
predicting viability. 11C has a half-life of 20.4 min and maximum 
b+ energy 0.96 MeV. It is obtained from an on-site cyclotron by 
reacting 11C-carbon dioxide with ethyl-magnesium bromide fol-
lowed by hydrolysis and purification. 11C-acetate is predominantly 
metabolized to 11C-carbon dioxide, which clears from the heart and 
is exhaled through the lungs. The efflux rate closely correlates with 
myocardial oxygen consumption over a wide range of flow, sub-
strate use, and metabolic conditions. Rapidly accumulates in 
the heart, lungs (3.5%), kidneys, liver (7.5%), pancreas, spleen, 
stomach, bowel (9%) and bone marrow, followed by washout from 
all organs though most rapidly from the heart. It is not excreted 
via the kidneys [17]. 
Hypoxia 
Abnormalities in tissue oxygenation underlie many of the 
metabolic and contractile changes that occur in ischemic myocar-
dium. As mentioned above, 11C-acetate can be used to indirectly 
assess myocardial oxygen consumption. The use of 15O is a more 
direct way to image myocardial oxygen consumption, but its use 
is quite complicated and limited to the centers with cyclotrons. 
Most of the tracers for imaging hypoxia that were developed so 
far are nitroimidazole based [22]. Nitroimidazoles are a class of 
lipophilic compounds with high electron affinity that have been 
developed as radiosensitizers of hypoxic regions in tumors [23]. 
These compounds readily diffuse through the cells. The nitro group 
can be chemically reduced to form a radical, which under normal 
oxygen content will react to regenerate the parent compound and 
diffuse out of the cell. Under hypoxic conditions, the nitro radical 
can interact with intracellular macromolecules and are trapped. 
Hypoxia tracers such as 18F-fluoromisonidazole (18F-MISO) and 
62/64Cu-ATSM are selectively trapped in hypoxic tissue by a biore-
ductive mechanism and result in hot spot images [24]. 
[18F]Fluoromisonidazole
[18F]Fluoromisonidazole (18F-MISO; Fig. 3) can be easily radio-
labelled by reacting 2-nitroimidazole with 18F-labeled epifluorohy-
drin or by fluorination of O-THP protected tosylate of misonidazole 
followed by acidic deprotection.
64Cu-ATSM
 [64Cu(II)]-diacetyl-bis(N4-methylthiosemicarbazone 
(64Cu-ATSM; Figure 4) is a promising agent for the imaging of 
hypoxic tissues. Copper-64 (T1/2=12.7 hours;  b
+, 0.653 MeV (17.8 
%);  b–, 0.579 MeV (38.4 %)) has decay characteristics that allow 
for positron emission tomography (PET) imaging and targeted 
radiotherapy of cancer. With a high membrane permeability and 
redox potential, a lipophilic 64Cu-ATSM conjugate is preferentially 
taken up by hypoxic cells compared to normoxic cells [25]; the 
extent of retention in tissue is inversely related to the state of tis-
sue oxygenation allowing the quantification of tissue hypoxia by 
Figure 3. [18F]Fluoromisonidazole (1­([18F]fluoro­3­(2­nitro­imida­
zol­1­yl)­propan­2­ol)
Figure 4. Structure of 64Cu­ATSM (64Cu(II)­diacetyl­bis(N4­methylthio­
semicarbazone)
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positron emission tomography (PET). In addition, the radioactive 
copper moiety of this agent may deliver a selective cytotoxic dose 
of beta radiation to hypoxic tumor cells.
Myocardial glucose metabolism 
Fludeoxyglucose (18F) injection 
USP [10], Ph. Eur. [11] (monograph 1325). 2-Deoxy-2-[18F]
fluoroglucose (18F-FDG; Fig. 5) with the half-life of 18F of 110 min 
has been used for measuring glucose metabolism in humans. 
It is commonly produced by nucleophilic substitution reaction 
of a O-acetyl-protected mannose triflate with [18F]fluoride (reso-
lubilized in acetonitrile in the presence of K2CO3 and Kryptofix 
222) followed by acid hydrolysis. The final tracer is purified using 
a mixed cation-anion exchange column [26]. 
Under physiological, fasting circumstances, the heart de-
pends on the breakdown of long-chain fatty acids for energy 
needed for contraction. However, after a carbohydrate meal or 
with myocardial ischemia, the pattern of substrate switches to 
glucose. FDG is a glucose analog with a metabolic pattern dif-
ferent from native glucose. FDG is initially extracted at a rate 
different than glucose. 18F-FDG is rapidly cleared from circulation 
with the half-time < 1 min. Three phases can be identified with 
half-lives of 0.2–0.3 min, 10–13 min and 80–95 min. About 30% 
is excreted via kidneys. Tissues of highest retention are the heart 
and brain. Following myocardial uptake, FDG is phosphorylated to 
FDG-6-phosphate and is then trapped in the myocardium because 
unlike phosphorylated glucose, it is a poor substrate for glycogen 
synthesis, the fructose phosphate shunt and glycolysis. Regional 
myocardial uptake of FDG therefore reflects relative distribution of 
regional rates of exogenous glucose utilization [4, 5]. 
Radiotracers for myocardial sympathetic 
nerve imaging
Regional and global abnormalities of cardiac sympathetic 
nervous function are involved in various clinical disorders, such 
as myocardial infarction, hypertrophic cardiomyopathy and 
congestive heart failure. The major neurotransmitter of the sym-
pathetic nervous system is norepinephrine, which is taken up by 
the transporter from circulation and stored in neuronal vesicles by 
vesicular monoamine transporter. Several radiolabelled analogs of 
noreponephrine have been developed, including PET tracers such 
as radiolabelled catecholamine analogues: 6-18F-fluorodopa-
mine, (-)-6-18F-fluoroepinephrine, and (-)-11C-epinephrine and 
catecholamie analogues such as 11C-meta-hydroxyephedrine, 
18F-fluorometaraminol and 11C-phenylephrine [4, 17]. However, the 
most widely used tracer is 123I-labelled meta-iodobenzylguanidine 
(123I-MIBG) [27].
Iobenguane (123I) injection 
USP [10], Ph. Eur. [11] (monograph 1113). 1-(3-[123I]iodoben-
zyl)guanidine (123I-MIBG, 123I-Iobenguane; Figure 6) shares the cel-
lular transport and storage mechanism with norepinephrine. Both 
enter the neuronal cells and are stored in chromaffin granules and 
secreted in response to acetylcholine. 123I-MIBG is rapidly taken 
up by sympathetic nerves. A profound loss of 123I-MIBG uptake 
is observed in affected myocardium, similar loss of uptake was ob-
served in patients with heart transplants [4]. 
Future trends
Radionuclide imaging of angiogenesis
Angiogenesis is defined as the process of sprouting new capil-
laries from preexisting microvessels. The main targets of imaging 
have been anb3 integrin and vascular endothelial growth factor 
(VEGF). Arginine-glycine-aspartate (RGD) is a peptide sequence 
that binds integrin, and the derivatives labeled with 18F [28, 29] and 
64Cu [30] have been evaluated in patients with cancer. An antibody 
which binds to VEGF has been labeled with 124I [31]. 
64Cu-6DOTA-VEGF121 — a PET tracer has been also developed 
for imaging angiogenesis [32].
Radionuclide imaging in apoptosis and necrosis
Apoptosis is an indicator of variety of conditions within the heart, 
including ischemia/reperfusion injury, autoimmune myocarditis, 
areas at risk following acute myocardial infarction, and in transplant 
rejection. The protein annexin V, which binds to phosphatidyl choline 
externalized by cells undergoing apoptosis, has been labeled with 
99mTc for SPECT [33, 34]. 99mTc-labelled annexin V was subsequently 
utilized in humans to detect in vivo cell death in patients presenting 
with myocardial infarction. Regional retention of 99mTc-labelled an-
nexin V correlated with the perfusion defect identified 6-8 weeks after 
discharge, providing a proof of concept that annexin-V imaging 
can be utilized for noninvasive detection of myocardial cell death. 
Annexin V has been labeled with 18F [35], 124I [36] and 68Ga [37] for 
PET imaging. Recently, the first-in-humans study with 18F-labelled 
2-(5-fluoropentyl)-2-methyl malonic acid (18F-ML-10), a small-mole-
cule PET tracer for apoptosis, has been also reported [38].
Figure 5. Structure of 18F­FDG (2­[18F]fluoro­2­deoxy­D­glucose)
Figure 6. Structure of 123I­MIBG (1­(3­[123I]iodobenzyl)guanidine)
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Summary
Although the myocardial perfusion studies have a well established 
role in the management of cardiac disorders, still the numbers of 
radiopharmaceuticals are under development for a variety of specific 
cardiac indications and their eventual clinical role remains to be seen. 
Table 2 provides the summary of cardiac imaging tracers in use and 
also at advanced stage of development, including their physical 
half-life, photon energy and possible applications in cardiac imaging. 
Molecular imaging is a new and evolving field that em-
ploys a targeted approach to noninvasively assess biologic pro-
cesses in vivo [39]. Some of the receptor targeting tracers have 
been described in this review. Other myocardial receptors are 
explored as potential targets for radionuclide imaging, such 
as a- and b-adrenergic receptors, muscarinic or benzodiazepine 
receptors. A noninvasive imaging technique to assess the receptor 
density and drugs binding to these receptors would provide new 
insights into the etiology of myocardial disease. 
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